The TLR5-agonist flagellin (FLG) is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. The proinflammatory activity of bacterial FLG has been well documented in leukocytes although the effects on airway epithelial function are less clear.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001June 14, 2021 - 9:00 am
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
- Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical OfficerFebruary 10, 2020 - 9:00 am
Follow Us On Twitter
Congratulations @EmilysEntourage for hitting the $10M fundraising mark since founding, raising over $918,000 at its 10th winter gala! This achievement will support the charity’s goal of finding a cure for #nonsensemutations of #CF: https://rb.gy/c7k6e7 #respiratorydisease